What Is Unicycive Therapeutics, Inc. (UNCY) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Unicycive Therapeutics, Inc. at its current price of $5.02. The composite intrinsic value is estimated at $5.03 (+0.3% average return), with 5 models flagging overvaluation risk. Notably, First Chicago sees the most upside at +144.4% (fair value: $12.27), while Markov DDM is the most conservative at -88.9% ($0.56). The spread between these extremes — +233.3% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About UNCY?
9 of 13 models are currently active for UNCY. Of these, 4 models suggest upside while 5 models suggest overvaluation. The Bayesian DCF estimates UNCY's intrinsic value at $2.64, implying -47.4% downside from the current price. See which stocks rank higher →
How Does UNCY Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, UNCY ranks #334 by Quality of Company score. CirclFi's QOC score of 4.0/10 evaluates 32 fundamental signals. A score of 4.0 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Unicycive Therapeutics, Inc. operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating UNCY should weigh these sector-specific dynamics alongside our model-derived fair values.
Is UNCY a Value Trap?
CirclFi's Value Trap algorithm assigns UNCY a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Unicycive Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Unicycive Therapeutics, Inc.'s fundamental quality profile registers 4.0/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +233.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every UNCY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across UNCY's 9 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad